Browse
Submit Data
Databases
API
Help

Dataset Information

11 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Topical rapamycin for facial angiofibromas in tuberous sclerosis complex.

ABSTRACT: Facial angiofibromas are a common cutaneous manifestation of tuberous sclerosis complex. Although angiofibromas are usually asymptomatic, they can be highly disfiguring and can have a significant impact on patient quality of life. Treatment for facial angiofibromas is challenging. Recently, topical rapamycin has been proposed as an effective option to treat angiofibromas. Herein is reported a case of a 27-year-old woman whose facial angiofibromas were successfully treated with topical rapamycin without relevant side effects.

SUBMITTER: Safa G

PROVIDER: S-EPMC5496009 | biostudies-other | 2017 Jul

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.

Project description: Not available

| S-EPMC6128508 | biostudies-literature

Rapamycin and rapalogs for tuberous sclerosis complex.

Project description: Not available

| S-EPMC6458010 | biostudies-literature

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

Project description: Not available

| S-EPMC3937593 | biostudies-literature

Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex.

Project description: Not available

| S-EPMC3535343 | biostudies-other

Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin.

Project description: Not available

| S-EPMC3585992 | biostudies-literature

Rapamycin and dexamethasone during pregnancy prevents tuberous sclerosis complex associated cystic kidney disease

Project description:Chronic kidney disease is the main cause of mortality in patients with tuberous sclerosis complex disease (TSC). The mechanisms underlying TSC cystic kidney disease remain unclear with no available interventions to prevent cyst formation. Using targeted deletion of TSC1 in nephron progenitor cells, we showed that cysts in TSC1 null embryonic kidneys originate from injured proximal tubular cells with high mTOR complex 1 activity. Injection of rapamycin to pregnant mice inhibited the mTOR pathway and tubular cell proliferation in kidneys of TSC1 null offspring. Rapamycin also prevented renal cystogenesis and prolonged the life span of TSC newborns. Gene expression analysis of proximal tubule cells, identified sets of genes and pathways that were modified secondary to TSC1 deletion and rescued by rapamycin administration during nephrogenesis. Inflammation with mononuclear infiltration was observed in the cystic areas of TSC1 null kidneys. Dexamethasone administration during pregnancy decreased cyst formation not only by inhibiting the inflammatory response but also by interfering with the mTORC1 pathway. These results reveal novel mechanisms of cystogenesis in TSC disease and suggest new interventions prior to birth to ameliorate cystic disease in offspring.

2020-06-10 | GSE152165 | GEO

Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex.

Project description: Not available

| S-EPMC7433150 | biostudies-literature

Tuberous sclerosis complex renal disease.

Project description: Not available

| S-EPMC2992644 | biostudies-literature

Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis.

Project description: Not available

| S-EPMC6373010 | biostudies-literature

Renal Manifestations of Tuberous Sclerosis Complex.

Project description: Not available